RecruitingNCT07101770

A Prediction Model in Pregnant Women With Aplastic Anemia

Development and Validation of a Prediction Model for Adverse Pregnancy Outcomes in Women With Aplastic Anemia


Sponsor

Peking University People's Hospital

Enrollment

300 participants

Start Date

Nov 27, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Aplastic anemia (AA) is a rare haematologic disorder characterized by bone marrow failure and pancytopenia. Its occurrence during pregnancy is exceedingly rare but poses significant risks, including maternal hemorrhage, infections, and perinatal complications such as preterm birth and fetal growth restriction. Consequently, pregnancy with AA is highly perilous for both mothers and infants. Early management is critical to ensure the health of both the mother and the baby. However, there are currently no predictive tools available to assess adverse outcomes in pregnant women with AA. Our center plans to conduct a multicenter, combined retrospective and prospective cohort study.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying A combined retrospective and prospective observational follow-up for people with aplastic anemia, prediction model, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 20 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERA combined retrospective and prospective observational follow-up

A combined retrospective and prospective observational follow-up


Locations(1)

Peking University People's Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07101770


Related Trials